Baijin Life Science Holdings Limited (HKG:1466)

HKG:1466 Revenue

In the fiscal year ending March 31, 2026, Baijin Life Science Holdings had annual revenue of 89.30M HKD, down -34.12%. Baijin Life Science Holdings had revenue of 34.16M in the half year ending March 31, 2026, with 19.63% growth.

• Revenue: 89.30M
• Revenue Growth: -34.12%
• P/S Ratio: 11.90
• Revenue / Employee: 1.06M
• Employees: 84
• Market Cap: 1.06B

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	89.30M	-46.25M	-34.12%
Mar 31, 2025	135.56M	81.88M	152.54%
Mar 31, 2024	53.68M	-33.20M	-38.22%
Mar 31, 2023	86.88M	24.23M	38.68%
Mar 31, 2022	62.65M	19.32M	44.60%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 12, 2026

Data Sources Report a data error